Duncan Greenhalgh is a partner in Goodwin Procter's Business Law Department and is a member of its Life Sciences and Intellectual Property Transactions & Strategies Practices.

Dr. Greenhalgh counsels biotechnology, pharmaceutical, diagnostics and medical device companies, research institutions and hospitals in all areas of intellectual property law, with particular emphasis on the procurement and enforcement of patent rights. He has extensive experience developing and managing domestic and foreign patent portfolios, including developing, implementing and expediting complex prosecution strategies in the United States and abroad, and has participated in numerous post grant proceedings, including reissue, ex parte and inter partes reexamination, and interference proceedings in the United States, and foreign patent opposition proceedings. Dr. Greenhalgh has obtained patents for various FDA-approved diagnostics and therapeutics, and advises clients on Orange Book listing and life cycle management issues. He also conducts freedom-to-operate risk assessments, evaluates patent infringement and validity issues, and counsels clients on risk mitigation strategies.